Status:

COMPLETED

Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency

Lead Sponsor:

Galderma R&D

Conditions:

Midface Volume Deficit

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a randomized, evaluator-blinded, no-treatment controlled study in participants with Midface Volume Deficit and/or Midface Contour Deficiency.

Detailed Description

For Group A, after screening, eligible participants will be treated from day 1 and followed up for 24 months. The purpose of Group A was to confirm investigator's use of correct injection technique. ...

Eligibility Criteria

Inclusion

  • Signed and dated informed consent to participate in the study.
  • Men or women aged 18 years of age or older of Chinese origin.
  • Participants seeking augmentation therapy for the midface.
  • MMVS score of 2, 3 or 4 on each side of the face as assessed by the blinded evaluator.

Exclusion

  • Known/previous allergy or hypersensitivity to any of the constituents of the product.
  • Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or other amide-type anaesthetics.
  • History of severe or multiple allergies, such as anaphylaxis.
  • Previous tissue revitalization treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling or dermabrasion in the area to be treated within 6 months before treatment.
  • Previous surgery (including aesthetic facial surgical therapy or liposuction), piercing or tattoo in the area to be treated.
  • Previous tissue augmentation therapy or contouring with any permanent (non-biodegradable) or semi-permanent filler, autologous fat, lifting threads or permanent implant in the area to be treated.
  • Other condition preventing the subject from entering the study in the Investigator's opinion, e.g. participants not likely to avoid other facial cosmetic treatments, participants anticipated to be unreliable, unavailable or incapable of understanding the study assessments or having unrealistic expectations of the treatment result.

Key Trial Info

Start Date :

November 12 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 18 2022

Estimated Enrollment :

205 Patients enrolled

Trial Details

Trial ID

NCT04132518

Start Date

November 12 2019

End Date

July 18 2022

Last Update

January 7 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Galderma research site 3

Beijing, China

2

Galderma research site 4

Beijing, China

3

Galderma research site 5

Chengdu, China

4

Galderma research site 2

Guangzhou, China